New One-Year Data From REMICADE(R) SONIC Trial Show Sustained Efficacy Compared With Azathioprine In Treatment Of Crohn’s Disease

New long-term findings from the Phase 3b study of patients with moderately to severely active Crohn’s disease having inadequate response to conventional therapies, but naive to immunomodulators and biologic therapy, were presented at Digestive Disease Week today. Data from the SONIC study showed that a greater proportion of patients receiving REMICADE (infliximab) maintained steroid-free remission at one year, compared with patients receiving azathioprine alone.

More: continued here

Filed under: Clinical Trials on June 4th, 2009